[go: up one dir, main page]

BR9814014A - Composição para aplicação tópica tendo propriedades de melhora da penetração, e processos para administrar um agente ativo de modo tópico ou sistêmico, e, para reduzir a inflamação associada com aplicação tópica de um agente ativo de modo tópico ou sistêmico - Google Patents

Composição para aplicação tópica tendo propriedades de melhora da penetração, e processos para administrar um agente ativo de modo tópico ou sistêmico, e, para reduzir a inflamação associada com aplicação tópica de um agente ativo de modo tópico ou sistêmico

Info

Publication number
BR9814014A
BR9814014A BR9814014-0A BR9814014A BR9814014A BR 9814014 A BR9814014 A BR 9814014A BR 9814014 A BR9814014 A BR 9814014A BR 9814014 A BR9814014 A BR 9814014A
Authority
BR
Brazil
Prior art keywords
active agent
systemically
topical application
agent topically
penetration
Prior art date
Application number
BR9814014-0A
Other languages
English (en)
Other versions
BR9814014B1 (pt
Inventor
Vivien H W Mak
Stephen Grayson
Original Assignee
Cellegy Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22059554&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9814014(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cellegy Pharma Inc filed Critical Cellegy Pharma Inc
Publication of BR9814014A publication Critical patent/BR9814014A/pt
Publication of BR9814014B1 publication Critical patent/BR9814014B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

''COMPOSIçãO PARA APLICAçãO TóPICA TENDO PROPRIEDADES DE MELHORA DA PENETRAçãO, E PROCESSOS PARA ADMINISTRAR UM AGENTE ATIVO DE MODO TóPICO OU SISTêMICO, E, PARA REDUZIR A INFLAMAçãO ASSOCIADA COM APLICAçãO TóPICA DE UM AGENTE ATIVO DE MODO TóPICO OU SISTêMICO''. A invenção se baseia na tecnologia de liberação de drogas tópica e transdérmica. Particularmente, a presente invenção refere-se a melhora da penetração de drogas aplicadas de modo tópico ou sistêmico e com a redução de irritação da pele que com freq³ência acompanha a liberação de drogas tópica e transdérmica.
BRPI9814014-0A 1997-11-10 1998-11-09 Composição para aplicação tópica tendo propriedades de melhora da penetração BR9814014B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6498097P 1997-11-10 1997-11-10
US60/064980 1997-11-10
PCT/US1998/023750 WO1999024041A1 (en) 1997-11-10 1998-11-09 Penetration enhancing and irritation reducing systems

Publications (2)

Publication Number Publication Date
BR9814014A true BR9814014A (pt) 2000-09-26
BR9814014B1 BR9814014B1 (pt) 2014-10-07

Family

ID=22059554

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9814014-0A BR9814014B1 (pt) 1997-11-10 1998-11-09 Composição para aplicação tópica tendo propriedades de melhora da penetração

Country Status (17)

Country Link
US (3) US6319913B1 (pt)
EP (2) EP1030668A4 (pt)
JP (2) JP4139860B2 (pt)
KR (1) KR100648536B1 (pt)
CN (1) CN1172674C (pt)
AT (1) ATE418988T1 (pt)
AU (1) AU747041B2 (pt)
BR (1) BR9814014B1 (pt)
CA (1) CA2309688C (pt)
DE (1) DE69840426D1 (pt)
DK (1) DK1510213T3 (pt)
ES (1) ES2318233T3 (pt)
IL (1) IL136042A (pt)
NO (1) NO20002422L (pt)
NZ (1) NZ504423A (pt)
PT (1) PT1510213E (pt)
WO (1) WO1999024041A1 (pt)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2318233T3 (es) * 1997-11-10 2009-05-01 Strakan International Limited Sistemas mejoradores de la penetracion y reductores de la irritacion que comprenden testosterona.
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
CA2406064C (en) * 2000-04-26 2011-03-15 Watson Pharmaceuticals, Inc. Minimizing adverse experience associated with oxybutynin therapy
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7897559B2 (en) * 2000-06-29 2011-03-01 Parks L Dean Dermatological composition and kit containing avermectin compound for treating dermatological conditions
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
DE60143360D1 (de) 2000-08-03 2010-12-09 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
CN1473047A (zh) * 2000-08-30 2004-02-04 ������ҩ�����޹�˾ 治疗男性勃起功能障碍和增强性冲动的方法
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
CN100349572C (zh) * 2000-08-30 2007-11-21 尤尼麦德制药公司 提高妇女睾酮和相关类固醇浓度的方法
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
JP5039252B2 (ja) * 2000-08-31 2012-10-03 ユニメッド ファーマシューティカルズ，リミティド ライアビリティ カンパニー 性機能低下を治療するための医薬組成物及び方法
ES2283446T3 (es) * 2000-12-22 2007-11-01 DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL Composicion de gel basada en alcohol para el tratamiento del hipogonadismo por administracion transescrotal.
US20040176476A1 (en) * 2001-06-22 2004-09-09 Gyurik Robert J. Pharmaceutical composition
WO2003015789A2 (en) * 2001-08-15 2003-02-27 Leo Pharma A/S A pharmaceutical composition for dermal application
US20030175329A1 (en) * 2001-10-04 2003-09-18 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
US8226972B2 (en) 2001-12-20 2012-07-24 Femmepharma Holding Company, Inc. Vaginal delivery of drugs
HU230920B1 (hu) * 2002-03-15 2019-03-28 Besins Healthcare Luxembourg Sarl Depresszió kezelésére szolgáló androgén gyógyászati készítmények
BR0308584A (pt) * 2002-03-15 2005-02-22 Unimed Pharmaceuticals Inc Composição farmacêutica androgênica e método para tratamento de depressão
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US6959640B2 (en) * 2002-06-06 2005-11-01 Omega Patents, L.L.C. Device for magnetically treating materials and associated methods
KR20100055542A (ko) 2002-06-25 2010-05-26 애크럭스 디디에스 피티와이 리미티드 비정질 약학적 조성물을 이용한 경피전달속도의 제어
US7099713B2 (en) 2002-06-28 2006-08-29 Battelle Memorial Institute Skin conduction and transport systems
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
EP1556009B2 (en) 2002-10-25 2021-07-21 Foamix Pharmaceuticals Ltd. Cosmetic and pharmaceutical foam
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
CA2511995C (en) 2003-01-02 2012-03-13 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
USD511198S1 (en) 2003-02-18 2005-11-01 Omega Patents, L.L.C. Magnetic treatment device for fluids
USD500118S1 (en) 2003-02-18 2004-12-21 Omega Patents, L.L.C. Magnetic treatment device for fluids
FR2851470B1 (fr) * 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
WO2004075822A2 (fr) * 2003-02-20 2004-09-10 Besins International Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
US20050042182A1 (en) * 2003-08-13 2005-02-24 Moshe Arkin Topical compositions of urea
US20050037040A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of urea and ammonium lactate
US20050036953A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of ammonium lactate
FR2856926B1 (fr) * 2003-07-02 2005-09-30 Centre Nat Rech Scient Utilisation des n-alkanols comme activateurs du canal cftr
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050025833A1 (en) * 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
MXPA06003316A (es) 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Formulacion farmaceutica transdermica para minimizar los residuos en la piel.
US20050244502A1 (en) * 2004-04-28 2005-11-03 Mathias Neil R Composition for enhancing absorption of a drug and method
US7425340B2 (en) 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
EP1634583A1 (en) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
EP1802258A4 (en) 2004-09-13 2015-09-23 Chrono Therapeutics Inc BIOSYNCHRONE TRANSDERMAL MEDICINES
US20070042026A1 (en) * 2005-03-17 2007-02-22 Wille John J Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions
WO2007124250A2 (en) 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US8372040B2 (en) 2005-05-24 2013-02-12 Chrono Therapeutics, Inc. Portable drug delivery device including a detachable and replaceable administration or dosing element
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
ES2607454T3 (es) 2005-06-03 2017-03-31 Acrux Dds Pty Ltd Método y composición para el suministro transdérmico de testosterona
GB0518558D0 (en) * 2005-09-12 2005-10-19 Givaudan Sa Improvements in or related to organic compounds
FI3456329T3 (fi) 2005-10-12 2025-02-27 Besins Healthcare Lu Sarl Parannettu testosteronigeeli ja käyttömenetelmä
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US20080153789A1 (en) * 2006-12-26 2008-06-26 Femmepharma Holding Company, Inc. Topical administration of danazol
IN2009KN02397A (pt) 2007-01-11 2015-08-07 Acrux Dds Pty Ltd
US9283177B2 (en) * 2007-01-16 2016-03-15 Juventio, Llc Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic
WO2008089242A1 (en) * 2007-01-16 2008-07-24 Dermworx, Incorporated Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
CA2712120A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
CN101917945A (zh) * 2008-05-21 2010-12-15 帝国制药美国公司 通过透皮给予非甾族抗炎药来治疗痛经
CA2730787A1 (en) * 2008-07-16 2010-01-21 David M. Cohen Topical drug delivery system
KR20110090892A (ko) * 2008-10-31 2011-08-10 모베르그 데르마 아베 두 개 이상의 침투 증강제의 조합으로 구성되는 국소 조성물
DK2373305T3 (en) * 2008-12-11 2017-05-15 Besins Healthcare Lu Sarl TRANSDERMAL PHARMACEUTICAL COMPOSITIONS INCLUDING A SERM
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
EP4249001A3 (en) 2009-08-21 2023-11-29 Novan, Inc. Topical gels
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
US8174881B2 (en) 2009-11-24 2012-05-08 Micron Technology, Inc. Techniques for reducing disturbance in a semiconductor device
CN102309669B (zh) * 2010-07-08 2013-07-03 高健生 一种治疗变态反应性结膜炎的中药制剂
JP6912852B2 (ja) 2010-11-18 2021-08-04 ホワイト マウンテン ファーマ，インコーポレイテッド 対象における慢性または解決不能な疼痛を処置するための、および／または痛覚閾値を高めるための方法、およびこれに用いる医薬組成物
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
MX2013013369A (es) * 2011-05-15 2014-10-17 Trimel Biopharma Srl Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino.
BR112014000178A2 (pt) 2011-07-05 2017-02-07 Novan Inc composições tópicas
WO2013006643A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
CN102335390B (zh) * 2011-09-30 2013-01-02 王巍 一种治疗面部湿疹的洗剂
WO2013138075A1 (en) 2012-03-14 2013-09-19 Novan, Inc. Nitric oxide releasing pharmaceutical compositions
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
US9855211B2 (en) * 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
WO2015021382A2 (en) 2013-08-08 2015-02-12 Novan, Inc. Topical compositions and methods of using the same
USD749225S1 (en) 2013-11-26 2016-02-09 Acrux Dds Pty Ltd Topical spreading applicator
USD750788S1 (en) 2013-11-26 2016-03-01 Acrux Dds Pty Ltd Topical spreading applicator
US8785426B1 (en) 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
EP3698775A1 (en) 2014-07-11 2020-08-26 Novan Inc. Topical antiviral compositions and methods of using the same
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
CN105813617B (zh) 2014-08-08 2021-05-28 诺万公司 局部用组合物和使用所述组合物的方法
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
JP2018511127A (ja) 2015-03-12 2018-04-19 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 渇望入力及び支援システム
US20170014417A1 (en) 2015-07-14 2017-01-19 Lipp Life Sciences Llc Pharmaceutical administration system for the transdermal application of vardenafil
CN107949389A (zh) * 2015-09-30 2018-04-20 富士胶片株式会社 经皮吸收用组合物
EP3423100A4 (en) 2016-03-02 2019-10-16 Novan, Inc. COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION AND METHOD FOR THE TREATMENT THEREOF
BR112018070578A2 (pt) 2016-04-13 2019-02-12 Novan, Inc. composições, sistemas, kits, e métodos para tratar uma infecção
MX2020012139A (es) 2016-09-08 2021-01-29 Vyne Pharmaceuticals Inc Composiciones y metodos para tratar rosacea y acne.
JP2020503950A (ja) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 経皮薬剤送達の装置及び方法
US10821075B1 (en) 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
JP7551496B2 (ja) 2017-10-31 2024-09-17 カリヴィル イムノセラピューティクス， インコーポレイテッド 全身送達のためのプラットフォーム腫瘍溶解性ベクター
EP3758679A4 (en) 2018-03-01 2021-12-15 Novan, Inc. NITROGEN OXIDE SUPPLIES AND METHOD OF USE THEREOF
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
BR112021007877A2 (pt) 2018-10-26 2021-08-03 Viramal Limited composição em gel mucoadesiva
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
EP3659583B1 (en) 2018-11-30 2023-06-07 Viramal Limited A method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent
JP2023552289A (ja) 2020-11-19 2023-12-15 カリヴィル イムノセラピューティクス， インコーポレイテッド 腫瘍微小環境リモデリングによる腫瘍溶解性免疫療法
TW202305125A (zh) 2021-04-30 2023-02-01 美商凱立凡爾免疫治療股份有限公司 用於經修飾mhc表現之溶瘤病毒

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US175329A (en) * 1876-03-28 Improvement in processes of preserving burial-cases
CA1165240A (en) 1980-07-09 1984-04-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
JPS59134710A (ja) 1983-01-21 1984-08-02 Suntory Ltd 発酵養毛化粧料
US4552872A (en) 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
US4537776A (en) * 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
US4557934A (en) * 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
JPS6067409A (ja) 1983-09-22 1985-04-17 Suntory Ltd 頭髪用化粧料
US4743588A (en) * 1984-06-13 1988-05-10 Allergan Pharmaceuticals, Inc. Compositions and methods of enhancing transdermal and transmembrane penetration systemic agents
US5196410A (en) * 1986-10-31 1993-03-23 Pfizer Inc. Transdermal flux enhancing compositions
ATE77559T1 (de) * 1986-11-14 1992-07-15 Theratech Inc Erhoehung des penetrationsvermoegens mittels eines aus die zellhuelle veraendernden substanzen und kurzkettigen alkoholen bestehenden binaeren systems.
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
ATE80313T1 (de) * 1988-02-29 1992-09-15 Pfizer Mittel zur erhoehung des transdermalen penetrationsflusses.
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4855294A (en) * 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
US5154922A (en) * 1988-12-01 1992-10-13 Schering Corporation Compositions for transdermal delivery of estradiol
DE68927675T2 (de) * 1989-08-23 1997-07-10 Hitachi Ltd Verfahren zur Richtigstellung von Netzwerkwichtungsfaktoren in einer mehrschichtigen Perceptronvorrichtung und eine solche Vorrichtung mit Mitteln zur Ausführung dieses Verfahrens
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
KR100256715B1 (ko) * 1991-08-26 2000-05-15 스티븐 에프. 웨인스톡 치료제의 설하 또는 구강 투여를 위한 조성물
KR950701508A (ko) * 1992-06-11 1995-04-28 챨스 디 에버트 경피식 약물수송을 조절하기 위한 글리세린의 용도(the use of glycerin in moderating transdermal drug delivery)
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
WO1995029678A1 (en) * 1994-04-28 1995-11-09 F.Hoffmann-La Roche Ag Pharmaceutical composition for transdermal delivery
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5780050A (en) * 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
AU1429697A (en) * 1995-12-29 1997-07-28 Cygnus, Inc. Systems and methods for the transdermal administration of androgenic agents
IT1283102B1 (it) * 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
US5760096A (en) * 1996-10-18 1998-06-02 Thornfeldt; Carl R. Potent penetration enhancers
EP0942697A1 (en) * 1996-10-30 1999-09-22 THERATECH, INC. (a Delaware Corporation) Fatty acid esters of lactic acid salts as permeation enhancers
ES2318233T3 (es) * 1997-11-10 2009-05-01 Strakan International Limited Sistemas mejoradores de la penetracion y reductores de la irritacion que comprenden testosterona.
US6465009B1 (en) 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
US20030175329A1 (en) 2001-10-04 2003-09-18 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment

Also Published As

Publication number Publication date
ES2318233T3 (es) 2009-05-01
EP1510213A2 (en) 2005-03-02
NO20002422D0 (no) 2000-05-10
AU1313299A (en) 1999-05-31
NO20002422L (no) 2000-06-21
IL136042A0 (en) 2001-05-20
IL136042A (en) 2005-12-18
CA2309688A1 (en) 1999-05-20
CN1285749A (zh) 2001-02-28
AU747041C (en) 1999-05-31
CA2309688C (en) 2007-04-24
DE69840426D1 (de) 2009-02-12
PT1510213E (pt) 2009-02-12
US7157097B2 (en) 2007-01-02
EP1030668A4 (en) 2002-09-25
EP1510213B1 (en) 2008-12-31
EP1510213A3 (en) 2005-03-23
NZ504423A (en) 2003-04-29
US6579865B2 (en) 2003-06-17
US6319913B1 (en) 2001-11-20
JP2001522804A (ja) 2001-11-20
EP1030668A1 (en) 2000-08-30
KR20010031984A (ko) 2001-04-16
JP2005047932A (ja) 2005-02-24
JP4139860B2 (ja) 2008-08-27
ATE418988T1 (de) 2009-01-15
CN1172674C (zh) 2004-10-27
BR9814014B1 (pt) 2014-10-07
KR100648536B1 (ko) 2006-11-24
WO1999024041A1 (en) 1999-05-20
US20020058650A1 (en) 2002-05-16
US20030166625A1 (en) 2003-09-04
AU747041B2 (en) 2002-05-09
DK1510213T3 (da) 2009-03-23

Similar Documents

Publication Publication Date Title
BR9814014A (pt) Composição para aplicação tópica tendo propriedades de melhora da penetração, e processos para administrar um agente ativo de modo tópico ou sistêmico, e, para reduzir a inflamação associada com aplicação tópica de um agente ativo de modo tópico ou sistêmico
BR9917074A (pt) Composição cosmética ou famacêutica do tipoemulsão óleo-em-água que compreende um agentebiologicamente ativo micronizado e um sistemaemulsionante apropriado e processo detratamento cosmético
BR0014512A (pt) Tratamento tópico para infecções por estreptococos
EP0388306A3 (en) Method for treating pain associated with herpes-zoster and post-herpetic neuralgia by topical application of local anesthetics
WO2000027381A3 (en) Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions
KR930007444A (ko) 4-비페닐아세트 산(bpaa)를 함유하는 제약학적 조성물
BR0311939A (pt) composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico
BR0210104A (pt) Composição inibidora seletiva de ciclooxigenase-2 permeável à pele
BR0211673A (pt) Terapia dermal utilizando derivados de fosfato de agentes de transferência de elétrons
GEP20032884B (en) Skin Penetration Enhancing Components
BR9911656A (pt) Composição farmacêutica, processos para prevenção ou tratamento de diabetes em um mamìfero, para prevenção ou tratamento de complicações diabéticas em um mamìfero e para prevenção ou tratamento da tolerância a glicose prejudicada em um mamìfero, uso de um sensibilizador de insulina, e, proceso para reduzir os efeitos colaterais de um sensibilizador de insulina ou/ e um anorético administrado a um mamìfero diabético
WO2003028667A3 (en) Semisolid topical hormonal compositions and methods for treatment
DE69826644D1 (de) Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
DK1014954T3 (da) Transdermalt terapeutisk system
BR9814721A (pt) "uso de polióis, dispositivo apropriado para o tratamento ou profilaxia de infecção da mucosa causada por levedura em mamìferos, processo para tratamento terapêutico ou profilático de mamìferos sofrendo de ou sendo submetidos a um risco aumentado de infecção da mucosa causada por levedura, composição para uso neste trtatamento, e, preparação farmacêutica para uso no tratamento profilático ou terapêutico sistêmico ou tópico de infecções da mucosa causadas por levedura."
WO2004091498A3 (en) Alcohol-free transdermal insulin composition and processes for manufacture and use thereof
WO2001041550A3 (en) Topical anesthetic formulation
AU1865100A (en) Hyaluronate lyase used for promoting penetration in topical agents
EP0766960A4 (en) PREPARATIONS FOR EXTERNAL USE FOR THE TREATMENT OF DERMATOS
ATE178201T1 (de) Alkoholisches feuchtigkeitsspendendes after shave lotion
WO1999026589A3 (en) Composition for the treatment of burns, sunburns, abrasions, ulcers and cutaneous irritation
AU4307993A (en) Topical application composition
AU7519500A (en) Pharmaceutical gel containing active substances
CO5011042A1 (es) Uso de una oxazolidinona para la fabricacion de un medicamento para administracion topica
PT1140001E (pt) Composicao para tratamento de queimaduras

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: CELLEGY PHARMACEUTICALS, INC. (US)

Free format text: TRANSFERIDO POR INCORPORACAO DE: CELLEGY PHARMACEUTICALS, INC.

B25G Requested change of headquarter approved

Owner name: CELLEGY PHARMACEUTICALS, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020080010135/RJ DE 21/01/2008.

B25A Requested transfer of rights approved

Owner name: STRAKAN INTERNATIONAL LIMITED (GB)

Free format text: TRANSFERIDO DE: CELLEGY PHARMACEUTICALS, INC.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/10/2014, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.